Press Releases

Press Releases

August 14, 2018
Establishment Labs Reports Second Quarter 2018 Financial Results

NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on improving patient safety and aesthetic outcomes, initially in the breast aesthetics and reconstruction market, reported financial results for the second quarter ended

August 7, 2018
Establishment Labs to Release Second Quarter 2018 Financial Results on August 14, 2018

NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Establishment Labs (NASDAQ: ESTA) today announced that the Company will release its second quarter 2018 financial results on Tuesday, August 14, 2018, prior to the open of U.S. financial markets. Establishment Labs will host a conference call and webcast

July 23, 2018
Establishment Labs Announces Closing of Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Common Shares
NEW YORK, July 23, 2018 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company focused on breast aesthetics and reconstruction technologies, today announced the closing of its initial public offering of 4,272,568 common shares, including the full
July 19, 2018
Establishment Labs Celebrates Initial Public Offering on the Nasdaq Stock Market
NEW YORK, July 19, 2018 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ:ESTA) today announced that the company’s common stock commenced trading on the Nasdaq Stock Market under the trading symbol “ESTA” following its initial public offering.
July 18, 2018
Establishment Labs Announces Pricing of Initial Public Offering
NEW YORK, July 18, 2018 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company focused on breast aesthetics and reconstruction technologies, today announced the pricing of its initial public offering of 3,715,277 common shares at a public offering
April 27, 2018
Establishment Labs Announces Motiva® Implants IDE Clinical Trial Underway with First Patient Enrolled and Surgery Completed
NEW YORK, April 27, 2018 (GLOBE NEWSWIRE) Establishment Labs Holdings Inc., a global medical device company focused on breast aesthetics and reconstruction technologies, today announced the enrollment and successful completion of implant surgery on the first patient in its U.S.
March 22, 2018
Establishment Labs Receives IDE Approval from U.S. FDA to Initiate Clinical Trial of Motiva Implants
NEW YORK, March 22, 2018 (GLOBE NEWSWIRE) Establishment Labs Holdings Inc., a global medical device company focused on breast aesthetics and reconstruction technologies with a strong emphasis on product development and innovation, announced today that it has received an investigational device
January 8, 2018
Establishment Labs Appoints Dennis Condon to the Board of Directors
NEW YORK, Jan. 8, 2018 (GLOBE NEWSWIRE) Establishment Labs, a global medical device company focused on breast aesthetics and reconstruction technologies with a strong emphasis on product development and innovation, announced today that Dennis Condon has been appointed to the Board of Directors. Mr.